* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Anitmicrobial Agents General Considerations 4 Pharmacology Prof
Discovery and development of non-nucleoside reverse-transcriptase inhibitors wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Compounding wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Psychedelic therapy wikipedia , lookup
Discovery and development of cephalosporins wikipedia , lookup
Pharmacognosy wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription costs wikipedia , lookup
Neuropharmacology wikipedia , lookup
Theralizumab wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Drug design wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Drug discovery wikipedia , lookup
Antimicrobial Agents (General considerations) Prof. R. K. Dixit Pharmacology and Therapeutics K.G.M.U. Lucknow [email protected] Objectives…. – Uses of antimicrobials (Therapeutic and Prophylaxis) – Culture and sensitivity testing – Selection of appropriate antimicrobials – Precautions while prescribing antimicrobials – Reasons for failure of antimicrobial treatment Bacteriological Culture and Sensitivity Testing • Plate – –Kirby-Bauer test • Strip–Epsilometer test • Dilution – –Test tubes Zones of inhibition (Kirby-Bauer) test Bacterial lawn Zone of inhibition E-Test (Epsilometer test) Zone of inhibition The E-test as an alternative method to the Kirby-Bauer test 5 Turbid tubes Test tubes Clear tubes Increasing concentration of drug Culture and Sensitivity Results • Minimum inhibitory concentration (MIC) – The lowest concentration of drug that prevents visible bacterial growth after 24 hours of incubation – Organism and antimicrobial specific – Interpretation • Drug’s activity versus the organism • Site of infection • Drug resistance • Report organism(s) and susceptibilities – Susceptible (S) – Intermediate (I) – Resistant (R) Culture Results Example Combination Therapy: Uses 1. Empirical therapy 2. Poly-microbial infections (Suspected mixed infection) 3. Prevent development of resistance Good combo is 2 bactericidal e.g. cell wall inhibitor & protein synthesis inhibitors Combination Antimicrobial Therapy • Synergistic • Antagonistic Uses of Antimicrobials in General Treatment and Prophylaxis CNS – Meningitis, Brain abscess Eye - Conjunctivitis, Blepharitis, Stye, Mouth and Face- Stomatitis, Gingivitis, Pulpitis, Pyorrhoea, Sinusitis ENT - Otitis, Rhinitis, Tonsillitis, Pharyngitis, Laryngitis, RTI- Tracheitis, Bronchitis, Bronchiolitis, Pneumonia, Pleuritis, Effusion, GITI- Dysentery, Gastroenteritis, Cholecystitis, Cholangitis, Appendicitis, UTI - Urethritis, Cystitis, Ureteritis, Pyelonephritis, Prostatitis, Epidydimitis Pelvic organ infections, Pelvic Organ Infections (PID)- Vaginitis, Cervicitis, Endometritis, STDs- Chancroid, Syphilis, Gonorrhoea, Non-specific urethritis (Chlamydia trachomatis), Granuloma inguinale, Donovanosis, Genital Herpes, Trichomonas Vaginitis Skin (and Soft tissue)- Boil, Carbuncles, Furuncles, Bone - Osteomyelitis, Special Infections- Typhoid, Tuberculosis, Leprosy, CNS Eye Mouth Sinuses ENT RTI GITI Skin Bones STD Special Selection of A Drug Disease of Intention Site, Intensity, Previous Tt, Co-morbid Diseases Other Drugs taken by Patient Physiological condition, Conscious / Unconscious, DDI and DFI, DOTI Financial Condition Selection of (ADR) Agent, Dose, Dosage form, Duration, Route, Choice of antimicrobial agents Patient• • • • • • • • • Age- Pediatric -----------General---------------------Geriatric General condition (G.C)- Consciousness etc….. Hepatic, Renal functionsOther metabolic factors PregnancyGenetics- (G-6-PD deficiency) Immune status of patientHistory of allergy Financial condition- Infection• • • • Site Type (Microbe)- Guess, Confirm with C/S Intensity Presence of pus, clot, Hematoma Drug• • • • • Spectrum Sensitivity Dosage form availability Relative Toxicity (selection depends on patient) Acceptable pharmacokinetic profile Selecting a Therapeutic Regimen • Confirm presence of infection: – History signs and symptoms Investigations • Predisposing factors • Before selecting Emperic therapy get material for c/s or for microscopy • Consider the spectrum of activity; – Narrow vs broad spectrum • Special conditions like – – – Sepsis or meningitis, Pt. with Diabetes, Immunosupression Pt. with other co morbid illnesses Antimicrobial therapy • Emperical –Infecting organism(s) not yet identified –Experience based on Site, Size, Season, Spectrum –More “broad spectrum” • Definitive –Organism(s) identified –Specific therapy (“narrow” spectrum) • Prophylactic or preventative Emperical therapy • Know the common pathogens responsible for common infections • Know the antimicrobial spectrum of activity • Take sample before starting Emperical therapy in complicated cases Is the Patient Infected??? • CAREFUL history and physical exam including relevant laboratory data and signs and symptoms – Temperature – White blood cell count (WBC) • WBC in normally sterile fluids (e.g. CSF) – Any swelling or erythema at a particular site – Purulent drainage – Other complaints • Predisposing factors – Surgery, Procedures, Co-morbid conditions including Diabetes, malignancy, immunosuppression etc. Selecting an Antimicrobial • Confirm the presence of infection – History, physical Signs and symptoms – Predisposing factors • Identification of pathogen – Collection of infected material – Culture and sensitivity – Staining and Serologies • Selection of presumptive therapy – Drug factors – Host factors • Monitor therapeutic response – Clinical assessment – Lab tests – Assessment of therapeutic failure Drug Factors Pharmacokinetics • • • • Absorption – IM, SC, topical, Oral, tube, or rectal administration – Bioavailability = amount of drug that reaches the systemic circulation Distribution – Affected by the drug’s lipophilicity, partition coefficient, blood flow , pH, and protein binding Metabolism – Phase I • Generally inactivate the substrate into a more polar compound • Dealkylation, hydroxylation, oxidation, deamination • Cytochrome P-450 system (CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2E1) – Phase II • Conjugation of the parent compound with larger molecules, increasing the polarity • Generally inactivate the parent compound • Glucuronidation, sulfation, acetylation Elimination – Total body clearance (Half life) • Renal + non-renal clearance • Steady state concentrations reached after 4-5 half lives • Affected by changes in end-organ function and protein binding Pharmacodynamics • Drug concentrations to their effect in the body – Desirable = Bacterial killing – Undesirable = Side effects • Bacteriostatic – Inhibit growth or replication • Bactericidal – Cause cell death Other Drug Factors • Adverse effect profile and potential toxicity • Resistance – Effects of the drug on the potential for the development of resistant bacteria in the patient, on the ward. • Cost – Acquisition cost + storage + preparation + distribution + administration – Monitoring – Length of hospitalization + readmissions – Patient quality of life • Pregnancy Host Factors – Fetus at risk of drug teratogenicity • Penicillin, cephalosporin, erythromycin appear safe – Altered drug disposition • intravascular volume, glomerular filtration rate, hepatic and metabolic activities • Genetic abnormalities – Glucose-6-phosphate dehydrogenase (G6PD) deficiency • Renal and hepatic function – Accumulation of drug metabolized excreted by these routes with impaired function – risk of drug toxicity unless doses adjusted accordingly • Underlying disease states – Predispose to particular infectious diseases or alter most likely organisms Site of Infection • Most important factor for antimicrobial selection • Defines the most likely organisms – Especially helpful in emperical antimicrobial selection • Determines the dose and route – Efficacy determined by adequate concentrations of antimicrobial at site of infection – Serum concentrations vs. tissue concentrations and relationship to MIC Site of Infection Will the antibiotic get there? • Choice of Agent, Dose, and Route important (ADR) – Oral vs. IV administration • Bioavailability, severity of infection, site of infection, function of GI tract – Blood and tissue concentrations • Ampicillin/piperacillin concentrations in bile • Fluoroquinolones concentrations in bone • Quinolones, TMP/SMX, concentrations in prostate – Ability to cross blood-brain barrier • Dependent on inflammation, lipophilicity, ,protein binding, ionization • 3rd or 4th generation Cephalosporin, Chloramphenicol, Ampicillin, Oxacillin – Local infection problems • Aminoglycosides inactivated by low pH and low oxygen tension • Sulphonamides are ineffective in presence of PUS (Due to……..) Concomitant Drug Therapy • Influences the selection of appropriate drug, dosage, and monitoring • Drug interactions – risk of toxicity or potential for efficacy of – May affect the patient and/or the organisms – Pharmaceutical Interactions – Pharmacokinetic interactions • Alter drug Absorption, Distribution, Metabolism, or Excretion – Pharmacodynamic interactions • Alter pharmacologic response of a drug • Selection of combination antimicrobial therapy ( 2 agents) Prophylactic use of antimicrobials in important conditions •Rheumatic fever•Benzathine Penicillin •Tuberculosis•Isoniazid, Rifampicin •Mycobacterium avium complex• Azithromycin, Clarithromycin •Pneumocystis – •Cotrimoxazole •HIV exposed person•Zidovudine + Lamivudine + Indinavir •HIV in foetus – •Zidovudine to mother •Meningococcal meningitis•Rifampicin / Sulfadiazine •Gonorrhoea / Syphilis•Ampicillin or Ceftrioxone •Genital herpes – • Acyclovir •Malaria•Chloroquine, Mefloquine •Influenza A•Amantadine •Cholera•Tetracyclines •Whooping cough – •Erythromycin •Plaque•Doxycycline •Bird flu•Oseltamivir (Tamiflu) •Dental extraction, Tonsillectomy, Endoscopies• Amoxicillin •Catherization•Cotrimoxazole, Norfloxacin, Ampicillin, Gentamicin •COPD•Ampicillin, Doxycycline •Immunocompromised•Penicillin, Cephalosporins ± Aminoglycosides ± Fluroquinolones± Metronidazole •General Surgical prophylaxis- BAM or CAM or FAM Monitoring Therapeutic Response • Clinical assessment – Improvement in signs and symptoms • Fever curve, WBC • Erythema, pain, cough, drainage, etc. • Laboratory tests Antimicrobial Factors in Drug Selection The Criteria of the Ideal Antibiotic: • • • • • • • • • Selectivity against microbes . Least toxic to the human cells Ability to reach at the desired site(BBB). Remains in body long enough to be effective Shelf life good Does not lead to resistance development Less expensive, Less allergic Microbiocidal rather than microbiostatic. Less suppression of normal flora Causes of failure of antimicrobial therapy •Improper selection of – •Drug, •Dose, •Duration •Dosage form and Route •Delay of treatment •Drug quality questionable •Failure to apply adjuvant measures •Immune-compromised status •Extra smart organism •Resistant, Dormant Summary • Antimicrobials are among the most important advances of modern medicine. • The general concept regarding antimicrobials – – – – – – – – – – – Antibacterial spectrum, Classification of antimicrobials Chemotherapeutic drugs Vs Pharmacodynamic drugs Bacteriostatic drugs, Vs Bactericidal drugs MIC Vs MBC Post antibiotic effect, General side effects of antimicrobials General Mechanisms of actions of antimicrobials (1-8) General Drug interactions of antimicrobials Antimicrobial ResistanceSelection of appropriate antimicrobial Causes of failure Summary • Appropriate selection of antimicrobials is complicated. • It is not only the matching a drug to a bug • Antimicrobial selection depends on – – – – Clinical efficacy, Adverse effect profile, Pharmacokinetic disposition, and Cost ultimately guide therapy • Once chosen, the dose, duration must be based on – – – – Age, Sex (pregnancy) and weight of the patient, Site, Severity of infection, Route of elimination, And other factors including co-morbid conditions • Use antimicrobials – Only when needed – For optimum time period as needed to treat the infection – Try to limit the emergence of bacterial resistance End of antibiotics - the ultimate consequence